Published in J Am Acad Dermatol on April 04, 2013
Comparison of outcomes in adults with pediatric-onset morphea and those with adult-onset morphea: a cross-sectional study from the morphea in adults and children cohort. Arthritis Rheumatol (2014) 0.96
Peripheral blood cytokine and chemokine profiles in juvenile localized scleroderma: T-helper cell-associated cytokine profiles. Semin Arthritis Rheum (2015) 0.75
A Case Report of Successful Treatment of Recalcitrant Childhood Localized Scleroderma with Infliximab and Leflunomide. Open Rheumatol J (2015) 0.75
Preliminary Results on the Feasibility of Using ARFI/SWEI to Assess Cutaneous Sclerotic Diseases. Ultrasound Med Biol (2015) 0.75
Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials (1989) 15.99
Inter and intraobserver variability of total skin thickness score (modified Rodnan TSS) in systemic sclerosis. J Rheumatol (1995) 4.11
Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol (1999) 2.60
Localized scleroderma in childhood is not just a skin disease. Arthritis Rheum (2005) 2.48
Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol (2002) 2.47
The Children's Dermatology Life Quality Index (CDLQI): initial validation and practical use. Br J Dermatol (1995) 2.12
The epidemiology of morphea (localized scleroderma) in Olmsted County 1960-1993. J Rheumatol (1997) 1.91
Update on morphea: part I. Epidemiology, clinical presentation, and pathogenesis. J Am Acad Dermatol (2011) 1.89
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol (2009) 1.35
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) (2009) 1.23
Localized scleroderma severity index and global assessments: a pilot study of outcome instruments. J Rheumatol (2008) 1.22
Quality of life measurement in dermatology: a practical guide. Br J Dermatol (1997) 1.20
An evaluation of long-term outcomes in adults with pediatric-onset morphea. Arch Dermatol (2010) 1.01
Methotrexate and corticosteroids in the treatment of localized scleroderma: a standardized prospective longitudinal single-center study. J Rheumatol (2012) 0.98
Juvenile-onset localized scleroderma activity detection by infrared thermography. Rheumatology (Oxford) (2002) 0.96
Pediatric scleroderma: systemic or localized forms. Pediatr Clin North Am (2012) 0.96
Discordance between patient and physician assessments of disease severity in systemic sclerosis. J Rheumatol (2010) 0.93
A new computerized method for the assessment of skin lesions in localized scleroderma. Rheumatology (Oxford) (2007) 0.89
20-MHz B-mode ultrasound in monitoring the course of localized scleroderma (morphea). Acta Derm Venereol Suppl (Stockh) (1991) 0.89
Initial evaluation of an ultrasound measure for assessing the activity of skin lesions in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2011) 0.88
Laser Doppler flowmetry for assessing localized scleroderma in children. Arthritis Rheum (2007) 0.88
MRI findings in deep and generalized morphea (localized scleroderma). AJR Am J Roentgenol (2008) 0.86
Childhood linear scleroderma: a possible role of thermography for evaluation. J Rheumatol (1992) 0.85
Development of consensus treatment plans for juvenile localized scleroderma: a roadmap toward comparative effectiveness studies in juvenile localized scleroderma. Arthritis Care Res (Hoboken) (2012) 1.84
The localized scleroderma skin severity index and physician global assessment of disease activity: a work in progress toward development of localized scleroderma outcome measures. J Rheumatol (2009) 1.35
Development and initial validation of the localized scleroderma skin damage index and physician global assessment of disease damage: a proof-of-concept study. Rheumatology (Oxford) (2009) 1.23
Cytokine profiles in localized scleroderma and relationship to clinical features. Cytokine (2011) 0.98
Improvement in medication education in a pediatric subspecialty practice. Pediatr Rheumatol Online J (2010) 0.79
Interferon-gamma inducible protein-10 as a potential biomarker in localized scleroderma. Arthritis Res Ther (2013) 0.78
Hypocomplementemia associated with macrophage activation syndrome in systemic juvenile idiopathic arthritis and adult onset still's disease: 3 cases. J Rheumatol (2011) 0.76
Coronary artery involvement in pediatric Takayasu's arteritis: Case report and literature review. Pediatr Rheumatol Online J (2013) 0.75
Index of suspicion. Pediatr Rev (2013) 0.75
Index of suspicion. Pediatr Rev (2008) 0.75